Tesamorelin vs CJC-1295 vs ipamorelin: what do the studies show?

Is tesamorelin the same as CJC-1295?

No. Tesamorelin and CJC-1295 are separate peptides, although both are analogues (lab-made look-alikes) of growth hormone-releasing hormone, or GHRH. Tesamorelin keeps the full 44-amino-acid human GHRH sequence and adds a hexenoyl group, a short carbon chain, at its start (Egrifta SV label, DailyMed, effective 29 July 2026). CJC-1295 is built on only the first 29 amino acids of GHRH, with four substitutions, and the with-DAC form adds one lysine that carries an albumin-binding group (Jetté et al., Endocrinology, 2005). Tesamorelin is an approved medicine (Drugs@FDA, BLA022505). CJC-1295 has no Drugs@FDA record (openFDA search, 14 October 2026).

Same family, different records. Your hypothalamus makes GHRH, and a plasma enzyme clips its front end within minutes: native GHRH had a half-life of 6.8 minutes in normal subjects, with no subject count in the abstract (Frohman et al., Journal of Clinical Investigation, 1986). In the CJC-1295 design paper, albumin conjugates of the GHRH(1-29) backbone showed enhanced stability against dipeptidylpeptidase-IV, a front-end-clipping enzyme, in a laboratory test that is not evidence about people (Jetté et al., Endocrinology, 2005).

The human evidence differs in size. Tesamorelin has a 412-person randomised trial in adults with HIV and abdominal fat and an approved label (Falutz et al., New England Journal of Medicine, 2007). CJC-1295 has three published human papers in healthy adults, from 2006 and 2009, and none reports a clinical outcome; the CJC-1295 pharmacokinetics page lays them out. The research material is a different molecule from the medicine, and nothing here suggests it is a substitute for tesamorelin or for any medicine.

Evidence limits

What do these comparisons not show?

Different people, different questions. The with-DAC studies enrolled healthy adults aged 21 to 61 (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006) and healthy men aged 20 to 40 (Ionescu and Frohman, Journal of Clinical Endocrinology & Metabolism, 2006). Tesamorelin's trial enrolled 412 adults with HIV, 86% of them men (Falutz et al., New England Journal of Medicine, 2007). Ipamorelin's human pharmacokinetic study used eight healthy men at each of five levels (Gobburu et al., Pharmaceutical Research, 1999). Age, health, sex and outcomes all differ, so a number from one study cannot be read against a number from another.

Which is stronger, CJC-1295 or tesamorelin, in published studies?

No human trial comparing CJC-1295 and tesamorelin was found among the PubMed records searched on 14 October 2026, and the two were measured on different outcomes. In two placebo-controlled studies of healthy adults aged 21 to 61, with no participant count in the abstract, one exposure to CJC-1295 with DAC raised mean growth hormone 2- to 10-fold for 6 days or more and mean IGF-I (insulin-like growth factor I, a hormone the liver makes in response to growth hormone) 1.5- to 3-fold for 9 to 11 days, as hormone-level results with no clinical outcome (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). In a 26-week trial of 412 adults with HIV and abdominal fat, tesamorelin raised IGF-I by 81.0% against a 5.0% fall on placebo, a result for an approved medicine in a different population that cannot be set against the CJC-1295 figures (Falutz et al., New England Journal of Medicine, 2007).

Half-life tells a different story from strength. The Egrifta SV label gives a half-life of 8 minutes and the Egrifta WR label 11 minutes in healthy subjects, with no participant count in the pharmacokinetics sections (DailyMed, effective 29 July 2026), while CJC-1295 with DAC had an estimated 5.8 to 8.1 days in healthy adults aged 21 to 61, with no participant count in the abstract (Teichman et al., 2006). How long a molecule lasts is one measure. How much growth hormone a pituitary releases in response is another, and no study found set the two peptides side by side on either measure.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC and without DAC differ by one added group. The with-DAC form is a 30-amino-acid peptide: the modified GHRH(1-29) backbone plus one lysine carrying a maleimide, a reactive chemical hook that bonds to albumin, a blood protein (Jetté et al., Endocrinology, 2005). DAC stands for drug affinity complex. The without-DAC form is the backbone alone. Teichman et al. estimated a human half-life of 5.8 to 8.1 days for the with-DAC form in two trials of healthy adults aged 21 to 61, with no participant count in the abstract, an estimate that does not describe the other form (Journal of Clinical Endocrinology & Metabolism, 2006). A PubMed search of CJC-1295 records on 14 October 2026 found no human half-life study of the without-DAC form and no study comparing the two forms.

Ionescu and Frohman sampled blood every 20 minutes overnight in healthy men aged 20 to 40, with no participant count in the abstract, one week after one exposure to the with-DAC form, and found that growth hormone pulses kept their rhythm while the lowest overnight levels rose 7.5-fold, mean growth hormone rose 46% and IGF-I rose 45%, a hormone-level result from one study with no clinical outcome (Journal of Clinical Endocrinology & Metabolism, 2006). No matching overnight study was found for the without-DAC form.

Labels blur the two. The Australian Poisons Standard names CJC-1295 with a CAS number and does not say with or without DAC (F2026L01327, read 14 October 2026), as the Australian legal status page explains, and the structure comparison sets the two sequences side by side.

Is CJC-1295 a steroid or a peptide?

CJC-1295 is a peptide, not a steroid. A peptide is a short chain of amino acids, the building blocks of proteins (TGA advisory, 13 April 2026), and CJC-1295 is a chain of 29 or 30 of them (Jetté et al., Endocrinology, 2005). Anabolic steroids belong to a different chemical family. The World Anti-Doping Agency's 2026 Prohibited List files CJC-1295 under S2, peptide hormones and related substances, as a growth hormone-releasing hormone analogue (S2.2.4), and files anabolic androgenic steroids separately under S1. The Australian Poisons Standard also lists them as separate entries (F2026L01327, October 2026).

Appendix D of the October 2026 Poisons Standard (F2026L01327, read 14 October 2026) lists 'ANABOLIC STEROIDAL AGENTS' as item 1 and CJC-1295 as item 7 of the same table, so the two sit in one list under separate names.

The confusion has a source. A 2026 critical review describes peptides as moving into sport after anabolic-androgenic steroids and as marketed as more selective and ostensibly safer alternatives, while noting that the clinical evidence supporting peptide use in sport is limited (Coutinho et al., Journal of Sports Medicine and Physical Fitness, 2026).

Is CJC the same as ipamorelin?

No. CJC-1295 and ipamorelin are different molecules that act on different receptors. CJC-1295 is a 29- or 30-amino-acid GHRH analogue that raised growth hormone in rats by activating the GHRH receptor on the pituitary, an animal result and not a human one (Jetté et al., Endocrinology, 2005). In primary rat pituitary cells, ipamorelin, a five-amino-acid peptide, stimulated growth hormone release through a GHRP-like receptor; this cell result does not establish a response in humans (Raun et al., European Journal of Endocrinology, 1998). In eight healthy men at each of five levels, ipamorelin's terminal half-life was about 2 hours (Gobburu et al., Pharmaceutical Research, 1999), against 5.8 to 8.1 days for CJC-1295 with DAC in healthy adults, with no participant count in the abstract (Teichman et al., 2006), and the two figures come from separate studies.

The receptor ipamorelin works through has a history. Howard et al. cloned a receptor from the pituitary and hypothalamus of swine and humans that growth hormone secretagogues, a family of small lab-made molecules, act on, in a laboratory cloning study (Science, 1996).

Ipamorelin's published phase 2 trial tested it in patients after bowel surgery. In 117 enrolled adults, 114 of them analysed, the median time to the first tolerated solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that was not statistically significant, in a small proof-of-concept study of patients with a broad range of conditions (p = 0.15; Beck et al., International Journal of Colorectal Disease, 2014). No human trial of CJC-1295 and ipamorelin tested together appeared in the PubMed records searched.

How does tesamorelin compare with CJC-1295 plus ipamorelin?

Tesamorelin is one peptide with an approved label and a randomised trial record, while CJC-1295 plus ipamorelin is a mix of two research peptides that no study found has tested together. Tesamorelin's evidence includes a 26-week randomised trial of 412 adults with HIV and abdominal fat, which describes that medicine in that population only (Falutz et al., New England Journal of Medicine, 2007). For the two-peptide mix, the human records are separate: CJC-1295 with DAC in healthy adults, with no participant count in the abstract (Teichman et al., 2006), and ipamorelin in eight healthy men at each of five levels and in a small proof-of-concept trial of 117 enrolled surgery patients (Gobburu et al., 1999; Beck et al., 2014). Neither record is evidence about the mix.

Reviews sort these peptides into tiers. A 2026 narrative review placed growth hormone-releasing hormone analogues and secretagogues in evidence tiers that run from regulatory-grade randomised trial data to no human studies at all, and flagged uncertainty about product composition in unregulated supply (Dominikowski et al., Frontiers in Endocrinology, 2026). A 2026 structured narrative review of peptide use in sports medicine described growth hormone-axis secretagogues including CJC-1295, ipamorelin and tesamorelin as investigational for the uses it examined, with uncertain safety and product-quality concerns (Villegas Meza et al., JBJS Reviews, 2026).

Is hexarelin better than CJC-1295, according to studies?

No study ranking them was found in the sources checked for this page. Hexarelin and CJC-1295 do not appear together in any human study among the records searched, and they are different kinds of peptide. Hexarelin is a synthetic six-amino-acid growth hormone-releasing peptide; in 12 healthy young volunteers, a short single-session study compared growth hormone release after hexarelin with release after GHRH and reported a larger release after hexarelin, in a study of hexarelin and not CJC-1295 (Ghigo et al., Journal of Clinical Endocrinology & Metabolism, 1994). CJC-1295 is a GHRH analogue. In 12 healthy older adults followed for 16 weeks, the growth hormone response to hexarelin was about 45% lower at week 16 than at baseline and, measured again four weeks after the study period, was not significantly different from baseline, in a study of hexarelin alone (Rahim and Shalet, Growth Hormone & IGF Research, 1998).

The regulator records list the two together. The Australian Poisons Standard lists hexarelin in Schedule 4 and at item 22 of Appendix D, beside CJC-1295 at item 7 (F2026L01327, October 2026), and the 2026 WADA Prohibited List names examorelin (hexarelin) in the same S2.2.4 group as CJC-1295. Neither entry says anything about which peptide performs better.

What have studies of CJC-1295 examined?

Published CJC-1295 studies measured how the peptide changes growth hormone and IGF-I levels; none found tested whether it changes muscle, fat or health outcomes in people. The human papers are a pair of placebo-controlled studies in healthy adults aged 21 to 61, with no participant count in the abstract (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006), an overnight growth hormone study in healthy men aged 20 to 40, with no participant count in the abstract (Ionescu and Frohman, 2006) and a blood-protein study in 11 healthy men (Sackmann-Sala et al., Growth Hormone & IGF Research, 2009), all reporting hormone-level or blood-test findings and not clinical outcomes. The one registered patient trial found, in HIV-associated abdominal fat (NCT00267527), is listed as terminated with no results. No trial of a CJC-1295 and ipamorelin mix exists in the records searched.

Marketing differs from findings. The TGA says unapproved peptide products are promoted with claims including weight loss, muscle growth, anti-ageing and enhancing cognitive and athletic performance, and that these products 'have not been evaluated for safety, quality or effectiveness by the TGA' (TGA advisory, 13 April 2026). A claim on a product page is not a result from a CJC-1295 study.

Has any study tested CJC-1295 for muscle growth?

No published human study of CJC-1295 found reports a muscle-growth result. The human studies measured growth hormone, IGF-I, hormone pulses and blood proteins (Teichman et al., 2006; Ionescu and Frohman, 2006; Sackmann-Sala et al., 2009). The one animal study found that tracked body composition used mice bred without GHRH, and relative lean mass was normal in every treated group, a result in a growth-deficient mouse model that does not describe healthy muscle or any human (Alba et al., American Journal of Physiology-Endocrinology and Metabolism, 2006). A 2026 critical review concluded that the clinical evidence supporting peptide use in sport is limited (Coutinho et al., Journal of Sports Medicine and Physical Fitness, 2026).

A hormone level is not a muscle measurement. A rise in IGF-I shows that the growth hormone axis responded; the abstracts reviewed for this page report hormone levels and serum proteins, not muscle size, strength or lean mass in people. Those are separate outcomes that would need their own measurement in their own trial.

What do reviews of CJC-1295 say?

Customer reviews and published reviews say different things. Customer and forum reviews are self-reports with no control group and no checked product identity; a 2016 study of 23 forum threads on female use recorded users' reasons and worries, not verified results, and it describes those forums only (Van Hout and Hearne, Substance Use & Misuse, 2016). Published review articles from 2026 describe the evidence as limited: a structured narrative review describes growth hormone-axis peptides including CJC-1295 as investigational for the sports-medicine uses it examined, with uncertain safety and product-quality concerns (Villegas Meza et al., JBJS Reviews, 2026), and a narrative review states that rigorous human safety data on unapproved peptides are scarce (Mendias and Awan, Sports Medicine, 2026).

Anecdote is not evidence. A trial uses a control group, measured outcomes and a record of what was in the vial; a forum post has none of those. The 2026 Frontiers in Endocrinology review adds that product composition and amounts in unregulated supply chains are uncertain (Dominikowski et al., 2026), so two people posting about the same product name may not have used the same material. The CJC-1295 and ipamorelin research guide covers what the studies cover.

Is research-use CJC-1295 the same material the studies used?

No. The with-DAC peptide in the published human studies was a trial product given to enrolled participants under study conditions (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006; Ionescu and Frohman, 2006). Research-use reference material is a laboratory compound. A study of one form does not describe a different form, and neither describes a catalogue blend. Research material is not a medicine, is not a substitute for one, and is not for human or animal use. The catalogue lists CJC-1295 (No DAC) and ipamorelin reference material as one blend in a single vial, and the listing gives no split between the two compounds.